This earnings season, so far, has had its share of disappointing beats and surprises, however, MoneyShow's Jim Jubak thinks these key factors make the season even more disappointing.
So far, in absolute numbers, this earnings season could be called somewhat disappointing. About 50% of the 10% of Standard & Poor's 500 (SPX) companies that have reported earnings, have beaten Wall Street estimates. That's below the long-term average of 63% and well below the four-year average of 74%.
But I think the earnings season, so far, is actually more disappointing than that absolute underperformance suggests. Too many of the earnings beats are by just a penny, or so, and too many earnings surprises are coupled with misses on revenue. Others combine an earnings beat with a cut to guidance for the first quarter, or all of 2014. And other companies are managing to report an earnings beat only thanks to a clearly one-time factor, or a bit of financial engineering using, frequently, share buybacks.
Top 5 Logistics Companies To Own For 2015: HCP Inc. (HCP)
HCP, Inc. is an independent hybrid real estate investment trust. The fund invests in real estate markets of the United States. It primarily invests in properties serving the healthcare industry including sectors of healthcare such as senior housing, life science, medical office, hospital and skilled nursing. The fund also invests in mezzanine loans and other debt instruments. It engages in acquisition, development, leasing, selling and managing of healthcare real estate and provides mortgage and other financing to healthcare providers. The fund benchmarks the performance of its portfolio against the S&P 500 Index, Berkshire Hathaway Index, and MSCI REIT Index. HCP, Inc. was formed in 1985 and is based in Long Beach, California with additional office in Nashville and San Francisco.
Advisors' Opinion:- [By Sue Chang and Saumya Vaishampayan]
HCP Inc. (HCP) �shares rose 2.3% after three days of losses. Analysts had expressed concerns over the abrupt dismissal of Chairman and Chief Executive James Flaherty last week.
- [By Sure Dividend]
Health care will be necessary until we find a cure for everything. There is a less than infinitesimal chance of us finding a cure for everything in the next several decades. The following companies are Dividend Aristocrats whose revenue is generated primarily in the health care sector:
HCP, Inc. (HCP) AbbVie (ABBV) Johnson & Johnson (JNJ) Abbott Laboratories (ABT) Walgreen (WAG) Medtronic (MDT) Becton Dickinson (BDX) Cardinal Health (CAH) C.R. Bard (BCR)Not to be outdone by the food and beverage industry (or perhaps due to negative health effects from the food and beverage industry), the health care industry counts nine Dividend Aristocrats in its ranks. They operate in more diverse lines of business than the food companies. HCP is a REIT that focuses on health care properties. C.R. Bard, Medtronic, and Becton Dickinson manufacture and distribute health care devices and supplies. Abbott Laboratories and Johnson & Johnson (and to a lesser extent, Cardinal Health) are well-diversified health care businesses. AbbVie was recently spun-off from Abbott Laboratories (notice the vaguely similar names), and is a pharmaceutical company.
- [By Dan Burrows]
Despite its prominence in the industry, ESV stock has been having a crummy year. It�� off more than 9% for the year-to-date and can’t expect much help from higher oil prices anytime soon. The slide is deep enough that adding in the big dividend yield still brings the ESV stock total return to -8.7%.
#4: HCP (HCP)HCP Dividend Yield: 5.83%
- [By Fredrik Arnold]
Results from David Fish's Dividend Champions Index compiled as of July 30, 2013 projecting price upside results one year hence showed HCP, Inc. (HCP), the healthcare properties real estate investment trust, posted a 9.45% upside to lead a pack of just four dogs this month.
Top Healthcare Technology Companies To Own In Right Now: Synageva BioPharma Corp (GEVA)
Synageva BioPharma Corp., incorporated in 1993, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products. It has several protein therapeutics in development, including two enzyme replacement therapies for lysosomal storage disorders and two programs for life-threatening genetic conditions. Its lead program, SBC-102, recombinant human lysosomal acid lipase (LAL), is its advanced pipeline program in clinical development for LAL Deficiency. This enzyme is responsible for the metabolism of cholesteryl esters and triglycerides that are delivered to lysosomes by a variety of routes, including low-density lipoprotein receptor mediated endocytosis. On November 2, 2012, Trimeris, Inc. merged with Synageva BioPharma Corp.
SBC-102 is produced by recombinant deoxyribonucleic acid (DNA) technology in egg white using its protein manufacturing platform. The Company has initiated natural history studies in approximately 20 countries. In addition to SBC-102, it is progressing protein therapeutic programs for other rare diseases, which are at different stages of preclinical development. These include two enzyme replacement therapies for other lysosomal storage disorders and two programs for other rare life-threatening conditions. As of December 31, 2011, its product candidate pipeline included SBC-102, SBC-103, SBC-104, SBC-105 and SBC-106.
SBC-104 is an extracellular protein that targets a severe, rare genetic condition. SBC-105 is an enzyme replacement therapy being developed to treat a severe, rare metabolic disorder. SBC-106 is a protein therapy that targets a severe and rare genetic condition.
Advisors' Opinion:- [By Garrett Cook]
Shares of Synageva BioPharma (NASDAQ: GEVA) were down 14.42 percent to $89.69 after the company reported that Phase 3 study met primary endpoint and six secondary endpoints across multiple disease-related abnormalities. Citigroup initiated coverage on Synageva BioPharma with a Neutral rating.
- [By Ben Levisohn]
Somaiya and team named Gilead and�Neurocrine Biosciences (NBIX) their top picks, hile putting Buy ratings on Celgene, Biogen Idec, Alexion (ALXN), Incyte (INCY), Pharmacyclics (PCYC) and Synageva (GEVA). BioMarin (BMRN), Infinity Pharmaceuticals (INFI) and Amgen (AMGN) earned Neutral ratings.
Top Healthcare Technology Companies To Own In Right Now: DexCom Inc.(DXCM)
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes, and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The company offers FDA approved SEVEN, which includes a disposable sensor that can be inserted by a patient and used continuously for up to seven days; a transmitter; and a small handheld receiver. Its SEVEN system also received CE Mark approval for commercialization in the European Union and the countries in Asia and Latin America that recognize the CE Mark. The company also provides the SEVEN PLUS, which incorporates additional user interface and algorithm enhancements that are intended to make its glucose monitoring function customizable. Its SEVEN PLUS has FDA and CE Mark approvals. DexCom has a collaboration agreement with Edwards Lifesciences LLC to develop products for conti nuously monitoring blood glucose levels in patients hospitalized for various conditions. It also has development agreement with Insulet Corporation to integrate its continuous glucose monitoring technology into Insulet?s wireless, handheld OmniPod System Personal Diabetes Manager; and a joint development agreement with Animas Corporation to integrate its continuous glucose monitoring technology into Animas insulin pumps. The company was founded in 1999 and is headquartered in San Diego, California.
Advisors' Opinion:- [By Sean Williams]
Where's the beef, DexCom?
Sometimes a company's products make a lot of sense on paper, but the practical application doesn't go nearly as smoothly. This is how I'd describe medical monitoring device maker DexCom (NASDAQ: DXCM ) , which has an array of glucose monitoring devices to help diabetes patients better manage their disease. Make no mistake about it; the number of diabetes diagnoses in this country is rising in accord with our obesity rate. Therefore, a company like DexCom, which makes the DexCom G4 System monitor, could be a big hit, and certainly has a wide enough audience to cater to. - [By Motley Fool Staff]
If we hope to halt or reverse those numbers, we'll need to approach patient care more holistically, and that could mean looking beyond drug therapies toward Dexcom's� (NASDAQ: DXCM ) continuous glucose monitoring sensors. Those sensors track and trend glucose levels, and alert patients when levels reach certain levels. By more accurately monitoring and treating these levels, patients might delay disease progression. That, in fact, could already be happening. Dexcom's sales jumped 60% in the past year to $68 million in the third quarter. But there's much work still to be done. Industry watchers estimate less than half of type 1 diabetics�and an even smaller percentage of type 2 patients�use monitors or insulin pumps to manage their disease.�
Top Healthcare Technology Companies To Own In Right Now: Iberdrola SA (IBE)
Iberdrola SA is a Spain-based company principally engaged in the energy sector. The Company's business is structured in four segments: Network Business, including all the energy transmission and distribution activities, and any other regulated activity originated in Spain, the United Kingdom, the United States and Brazil; Deregulated Business, including electricity generation and sales businesses as well as gas trading and storage businesses carried on by the Group in Spain, Portugal, the United Kingdom and North America; Renewable: activities relating to renewable energies in Spain, the United Kingdom, the United States and the rest of the world; Other Businesses, comprising the engineering and construction businesses and the non-power businesses; and Corporation which includes the costs of the Group's structure (Single Corporation), of the administration services of the corporate areas that are subsequently invoiced to the other companies through either specific service. Advisors' Opinion:- [By Sarah Jones]
Iberdrola SA (IBE), Spain�� biggest power company, fell 3.4 percent to 3.87 euros. Endesa SA (ELE) slumped 4.6 percent to 16 euros, while Acciona SA (ANA), which owns more than 4 gigawatts of wind farms in the country, tumbled 8.5 percent to 37.95 euros. Red Electrica Corp. slid 7.5 percent to 38.34 euros.
Top Healthcare Technology Companies To Own In Right Now: PIMCO Strategic Income Fund, Inc (RCS)
PIMCO Strategic Global Government Fund, Inc. (the Fund) is a closed-end bond fund. The Fund invests primarily in a portfolio of investment grade fixed-income securities of the United States and other countries. The Fund invests, under normal circumstances, at least 80% of its net assets plus borrowings for investment purposes in government securities, which include bonds issued or guaranteed by the United States or foreign governments, by their agencies, authorities or instrumentalities, or by supranational entities, and synthetic instruments.
Government securities also include mortgage-backed securities issued or guaranteed by certain United States Government agencies and government-sponsored enterprises, including Federal Home Loan Mortgage Corporation (Freddie Mac), Federal National Mortgage Association (Fannie Mae) and Government National Mortgage Association (Ginnie Mae), which may or may not be backed by the full faith and credit of the United States Government. The Fund also invests up to 20% of its total assets in non-investment grade securities regardless of the issuer, including corporate, mortgage-backed and asset-backed securities. Pacific Investment Management Company LLC is the Fund's investment adviser.
Advisors' Opinion:- [By Keith Fitz-Gerald]
I like the PIMCO Strategic Global Government Fund. The ticker is (RCS). The reason I like that, is it pays a hefty income; it's a bet on increased stability through further quantitative easing.
Top Healthcare Technology Companies To Own In Right Now: PrimeEnergy Corporation(PNRG)
PrimeEnergy Corporation, through its subsidiaries, engages in the acquisition, exploration, development, and production of crude oil and natural gas in the United States. Its principal properties are located in Texas, Oklahoma, West Virginia, the Gulf of Mexico, New Mexico, Colorado, and Louisiana. The company operates 1,600 oil and gas wells, as well as owns non-operating interests in approximately 800 additional wells. It also provides well-servicing support operations, site-preparation, and construction services for oil and gas drilling and reworking operations, as well as contract services for third parties. In addition, the company involves in the acquisition of producing oil and gas properties through joint ventures with industry partners. As of December 31, 2010, it had proved reserves of 101 billion cubic feet of gas equivalent. The company was founded in 1973 and is based in Stamford, Connecticut.
Advisors' Opinion:- [By Jake L'Ecuyer]
Leading and Lagging Sectors
Energy shares declined by just 0.08 percent in Monday's trading. However, top gainers in the sector included PrimeEnergy (NASDAQ: PNRG) and Dresser-Rand Group (NYSE: DRC). In trading on Monday, financial shares were relative laggards, down on the day by about 1.07 percent.
Top Healthcare Technology Companies To Own In Right Now: Star Bulk Carriers Corp.(SBLK)
Star Bulk Carriers Corp. operates as a shipping company providing seaborne transportation solutions in the dry bulk sector worldwide. Its vessels transport major bulks, which include iron ore, coal, and grain; and minor bulks, such as bauxite, fertilizers, and steel products. The company has an operating fleet of 15 dry bulk carriers consisting of 7 Capesize and 8 Supramax dry bulk vessels with a combined cargo carrying capacity of 1,625,945 deadweight tons. The company was incorporated in 2006 and is based in Athens, Greece.
Advisors' Opinion:- [By Igor Greenwald]
Last month, Oaktree Capital (OAK), managed by another distressed investing icon, Howard Marks, disclosed a huge 21.9% stake in Star Bulk Carriers (SBLK).
- [By James E. Brumley]
It's certainly no Safe Bulkers, Inc. (NYSE:SB) or Star Bulk Carriers Corp. (NASDAQ:SBLK), in terms or market cap or revenue. In fact, even with the drybulk shipping industry it's a somewhat obscure name. Yet, FreeSeas Inc. (NASDAQ:FREE) may well be the stock with the most near-term potential upside, now that it's gotten over a key technical hump.
- [By Roberto Pedone]
Star Bulk Carriers (SBLK) provides worldwide transportation of drybulk commodities through its vessel-owning subsidiaries for a range of customers and minor bulk cargoes including iron ore, coal, grain, cement and fertilizer. This stock closed up 7.9% at $10.58 in Monday's trading session.
Monday's Volume: 243,000
Three-Month Average Volume: 64,367
Volume % Change: 228%From a technical perspective, SBLK jumped sharply higher here right above some near-term support at $9.47 with above-average volume. This stock has been uptrending strong for the last two months and change, with shares moving higher from its low of $5.37 to its recent high of $11.53. During that move, shares of SBLK have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of SBLK within range of triggering a near-term breakout trade. That trade will hit if SBLK manages to take out its 52-week high at $11.53 and then once it clears some past resistance at $11.98 with high volume.
Traders should now look for long-biased trades in SBLK as long as it's trending above near-term support at $9.47 and then once it sustains a move or close above those breakout levels with volume that hits near or above 64,367 shares. If that breakout triggers soon, then SBLK will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are its next major overhead resistance levels at $14 to $15.
- [By James E. Brumley]
I'll warn you now that if you're a fan or shareholder of Star Bulk Carriers Corp. (NASDAQ:SBLK), then you're not going to like what you're about to read. Before you fly off into a tirade of "colorful" descriptions of me, however, know that this is neither a judgment call on the company itself, nor a long-term outlook. It's simply a trading-based observation of hints that SBLK has dropped today. Fair enough? OK, let's dig in.
No comments:
Post a Comment